Arjuna: Difference between revisions
No edit summary |
No edit summary |
||
| Line 31: | Line 31: | ||
}} | }} | ||
'''Terminalia arjuna''' (family | '''Terminalia arjuna''' (family Combretaceae), commonly referred to as '''Arjuna''', is one of the most prominent cardiovascular tonics in traditional [[Ayurveda|Ayurvedic]] pharmacology (''Hridya'').<ref name="Dwivedi2014">{{cite journal |last1=Dwivedi |first1=Shridhar |last2=Chopra |first2=Deepti |year=2014 |title=Revisiting Terminalia arjuna – An Ancient Cardiovascular Drug |journal=Journal of Traditional and Complementary Medicine |volume=4 |issue=4 |pages=224–231 |doi=10.4103/2225-4110.139103 |pmid=25379361 |pmc=4220503}}</ref> Used for over a millennium to treat chest pain, heart failure, hypertension, and dyslipidemia, modern clinical and pharmacological research has validated its multi-target mechanisms<ref name="Mould2023">{{cite journal |last1=Mould |first1=M. A. |last2=Sridhar |first2=M. |year=2023 |title=Terminalia arjuna, a Cardioprotective Herbal Medicine–Relevancy in the Modern Era of Pharmaceuticals and Green Nanomedicine—A Review |journal=Pharmaceuticals |volume=16 |issue=1 |pages=126 |doi=10.3390/ph16010126 |pmid=36678623 |pmc=9865188}}</ref>. The therapeutic profile of ''T. arjuna'' stem bark stems from a complex matrix of oleanane triterpenoids, triterpenoid glycosides, flavonoids, and hydrolyzable tannins that collectively confer anti-ischemic, anti-atherosclerotic, antihypertensive, and antioxidant cardioprotection.<ref name="Pauzi2021">{{cite journal |last1=Pauzi |first1=Ahmad Naim |last2=Lim |first2=Soo Tein |last3=Jantan |first3=Ibrahim |year=2021 |title=Arjunolic acid: A promising triterpenoid against cardiovascular and metabolic disorders |journal=Phytomedicine |volume=85 |pages=153540 |doi=10.1016/j.phymed.2021.153540 |pmid=33789182}}</ref> | ||
==Therapeutic Use== | ==Therapeutic Use== | ||
[[File:Arjuna.jpg|thumb|'''Arjuna (''Terminalia arjuna'')''']] | |||
Obesity (medoroga), wound management (vrana), heart diseases (hridroga), loss fof strength due to injury (kshatakshaya), obstinate urinary disorders including diabetes mellitus (prameha), thirst (trishna), melasma (vyanga)<ref>The Ayurvedic Pharmacopoeia of India. Department of Ayush, Ministry of Health and Family welfare, Govt. of India, New Delhi, Part I. 1986; Volume II:8</ref> | Obesity (medoroga), wound management (vrana), heart diseases (hridroga), loss fof strength due to injury (kshatakshaya), obstinate urinary disorders including diabetes mellitus (prameha), thirst (trishna), melasma (vyanga)<ref>The Ayurvedic Pharmacopoeia of India. Department of Ayush, Ministry of Health and Family welfare, Govt. of India, New Delhi, Part I. 1986; Volume II:8</ref> | ||
| Line 182: | Line 182: | ||
! Phytochemical Class !! Key Active Constituents !! Primary Pharmacological Roles | ! Phytochemical Class !! Key Active Constituents !! Primary Pharmacological Roles | ||
|- | |- | ||
| '''Oleanane Triterpenoids''' || | | '''Oleanane Triterpenoids''' || Arjunolic acid, Arjunic acid, Arjungenin, Terminic acid || Cardioprotective, anti-platelet, anti-apoptotic, and direct free-radical scavenging<ref name="Sinha2008">{{cite journal |last1=Sinha |first1=M. |last2=Manna |first2=P. |last3=Sil |first3=P. C. |year=2008 |title=Arjunolic acid, a novel phytomedicine with multifunctional therapeutic potential |journal=Natural Product Reports |volume=25 |issue=3 |pages=543–552 |doi=10.1039/B713728P |pmid=18497899}}</ref>. | ||
|- | |- | ||
| '''Triterpenoid Glycosides''' || Arjunetin, Arjunosides I–IV, Arjunglucosides I & II || Inotropic, chronotropic, and cardiac membrane-stabilizing activities. | | '''Triterpenoid Glycosides''' || Arjunetin, Arjunosides I–IV, Arjunglucosides I & II || Inotropic, chronotropic, and cardiac membrane-stabilizing activities. | ||
|- | |- | ||
| '''Flavonoids & Phenolics''' || Arjunone, Arjunolone, | | '''Flavonoids & Phenolics''' || Arjunone, Arjunolone, Baicalein, Luteolin, Quercetin || Endothelial nitric oxide stimulation, vasodilation, and inhibition of LDL oxidation. | ||
|- | |- | ||
| '''Hydrolyzable Tannins''' || | | '''Hydrolyzable Tannins''' || Punicalagin, Punicallin, Casuarinin, Terflavin C || Vascular astringency, anti-inflammatory, and extracellular matrix protection. | ||
|} | |} | ||
| Line 195: | Line 195: | ||
=== Cardioprotective & Anti-Ischemic Actions === | === Cardioprotective & Anti-Ischemic Actions === | ||
''T. arjuna'' extracts preserve myocardial structural integrity during ischemic events and reperfusion injury<ref name="Dwivedi2014"/>: | ''T. arjuna'' extracts preserve myocardial structural integrity during ischemic events and reperfusion injury<ref name="Dwivedi2014"/>: | ||
* '''Endogenous Antioxidant Preservation:''' Prevents the depletion of key intracellular antioxidant enzymes, including | * '''Endogenous Antioxidant Preservation:''' Prevents the depletion of key intracellular antioxidant enzymes, including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx)<ref name="Pauzi2021"/>. | ||
* '''Anti-Apoptotic Regulation:''' Downregulates pro-apoptotic markers ( | * '''Anti-Apoptotic Regulation:''' Downregulates pro-apoptotic markers (Bax, caspase-3) while upregulating anti-apoptotic proteins ([[Bcl-2]]) and heat shock proteins (HSP-70) in ischemic cardiomyocytes<ref name="Mould2023"/>. | ||
A double-blind, randomized, placebo-controlled crossover study evaluated 58 patients with chronic stable angina (NYHA Class II–III). Administration of 500 mg of ''T. arjuna'' bark extract every 8 hours significantly reduced anginal frequency and nitrate consumption, accompanied by objective improvements in treadmill exercise duration and reduced peak ST-segment depression compared to placebo<ref name="Bharani2002">{{cite journal |last1=Bharani |first1=A. |last2=Ganguly |first2=A. |last3=Bhargava |first3=K. D. |year=2002 |title=Efficacy of Terminalia arjuna in chronic stable angina: a double-blind, placebo-controlled, crossover study comparing Terminalia arjuna with isosorbide mononitrate |journal=Indian Heart Journal |volume=54 |issue=2 |pages=170–175 |pmid=12086380}}</ref>. Furthermore, clinical evaluations in congestive heart failure and ischemic heart disease demonstrate improved left ventricular ejection fraction<ref name="Vaidya2010">{{cite journal |last1=Vaidya |first1=A. B. |last2=Rajagopalan |first2=F. |last3=Kale |first3=A. Q. |year=2010 |title=Clinical evaluation of Terminalia arjuna in ischemic heart disease and congestive cardiac failure |journal=Journal of Association of Physicians of India |volume=58 |pages=411–416}}</ref>. | A double-blind, randomized, placebo-controlled crossover study evaluated 58 patients with chronic stable angina (NYHA Class II–III). Administration of 500 mg of ''T. arjuna'' bark extract every 8 hours significantly reduced anginal frequency and nitrate consumption, accompanied by objective improvements in treadmill exercise duration and reduced peak ST-segment depression compared to placebo<ref name="Bharani2002">{{cite journal |last1=Bharani |first1=A. |last2=Ganguly |first2=A. |last3=Bhargava |first3=K. D. |year=2002 |title=Efficacy of Terminalia arjuna in chronic stable angina: a double-blind, placebo-controlled, crossover study comparing Terminalia arjuna with isosorbide mononitrate |journal=Indian Heart Journal |volume=54 |issue=2 |pages=170–175 |pmid=12086380}}</ref>. Furthermore, clinical evaluations in congestive heart failure and ischemic heart disease demonstrate improved left ventricular ejection fraction<ref name="Vaidya2010">{{cite journal |last1=Vaidya |first1=A. B. |last2=Rajagopalan |first2=F. |last3=Kale |first3=A. Q. |year=2010 |title=Clinical evaluation of Terminalia arjuna in ischemic heart disease and congestive cardiac failure |journal=Journal of Association of Physicians of India |volume=58 |pages=411–416}}</ref>. | ||
=== Vascular Tone & Anti-Hypertensive Efficacy === | === Vascular Tone & Anti-Hypertensive Efficacy === | ||
* '''Endothelial Nitric Oxide Activation:''' Flavonoid and glycoside fractions stimulate | * '''Endothelial Nitric Oxide Activation:''' Flavonoid and glycoside fractions stimulate endothelial nitric oxide synthase (eNOS), increasing vascular [[Nitric oxide|NO]] availability and inducing endothelium-dependent vasodilation<ref name="Mould2023"/>. | ||
* '''Inotropic & Chronotropic Balance:''' Demonstrates positive inotropic (enhancing force of contraction) and mild negative chronotropic (regulating pulse rate) effects without increasing myocardial oxygen demand<ref name="Dwivedi2014"/>. | * '''Inotropic & Chronotropic Balance:''' Demonstrates positive inotropic (enhancing force of contraction) and mild negative chronotropic (regulating pulse rate) effects without increasing myocardial oxygen demand<ref name="Dwivedi2014"/>. | ||
=== Anti-Platelet & Anti-Atherosclerotic Effects === | === Anti-Platelet & Anti-Atherosclerotic Effects === | ||
* '''Thrombin-Induced Inhibition:''' The isolated triterpenoid '''arjunolic acid''' inhibits thrombin-induced | * '''Thrombin-Induced Inhibition:''' The isolated triterpenoid '''arjunolic acid''' inhibits thrombin-induced platelet aggregation with an <math>IC_{50}</math> of 0.048 mM—exhibiting greater potency than aspirin (<math>IC_{50} = 0.088\text{ mM}</math>)<ref name="Sinha2008"/><ref name="Pauzi2021"/>. | ||
* '''Lipid Modulation & Foam Cell Suppression:''' Reduces circulating total cholesterol, | * '''Lipid Modulation & Foam Cell Suppression:''' Reduces circulating total cholesterol, low-density lipoprotein (LDL), and triglycerides while raising high-density lipoprotein (HDL) via upregulation of PPAR-γ pathways and suppression of oxidative LDL modification<ref name="Dwivedi2014"/>. | ||
== Posology & Preparations == | == Posology & Preparations == | ||
| Line 228: | Line 228: | ||
* '''Adverse Reactions:''' Mild, transient gastrointestinal effects (such as mild constipation or dyspepsia) may occur due to the high tannin concentration. | * '''Adverse Reactions:''' Mild, transient gastrointestinal effects (such as mild constipation or dyspepsia) may occur due to the high tannin concentration. | ||
* '''Precautions & Interactions:''' | * '''Precautions & Interactions:''' | ||
** '''Anticoagulants & Antiplatelets:''' Given arjunolic acid's inhibitory effect on thrombin-induced aggregation, monitor coagulation metrics when co-prescribed with agents like | ** '''Anticoagulants & Antiplatelets:''' Given arjunolic acid's inhibitory effect on thrombin-induced aggregation, monitor coagulation metrics when co-prescribed with agents like Warfarin, Aspirin, or Clopidogrel<ref name="Sinha2008"/>. | ||
** '''Antihypertensives:''' Potential additive hypotensive effects; routine blood pressure monitoring is advised when integrated into existing antihypertensive regimens<ref name="Dwivedi2014"/>. | ** '''Antihypertensives:''' Potential additive hypotensive effects; routine blood pressure monitoring is advised when integrated into existing antihypertensive regimens<ref name="Dwivedi2014"/>. | ||
| Line 238: | Line 238: | ||
[https://cb.imsc.res.in/imppat/therapeutics/Terminalia%20arjuna IMPPAT database] | [https://cb.imsc.res.in/imppat/therapeutics/Terminalia%20arjuna IMPPAT database] | ||
[[Category:Database of herbs and minerals|Herbs]] | [[index.php?title=Category:Database of herbs and minerals|Herbs]] | ||